These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 25297756)

  • 1. [Standard of care and new drugs for diffuse large B-cell lymphoma].
    Yamamoto K
    Rinsho Ketsueki; 2014 Oct; 55(10):1920-8. PubMed ID: 25297756
    [No Abstract]   [Full Text] [Related]  

  • 2. Intensified chemotherapy for diffuse large B-cell lymphomas.
    Vose JM
    Lancet; 2011 Nov; 378(9806):1828-9. PubMed ID: 22118432
    [No Abstract]   [Full Text] [Related]  

  • 3. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
    Récher C; Coiffier B; Haioun C; Molina TJ; Fermé C; Casasnovas O; Thiéblemont C; Bosly A; Laurent G; Morschhauser F; Ghesquières H; Jardin F; Bologna S; Fruchart C; Corront B; Gabarre J; Bonnet C; Janvier M; Canioni D; Jais JP; Salles G; Tilly H;
    Lancet; 2011 Nov; 378(9806):1858-67. PubMed ID: 22118442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
    Thieblemont C; Tilly H; Gomes da Silva M; Casasnovas RO; Fruchart C; Morschhauser F; Haioun C; Lazarovici J; Grosicka A; Perrot A; Trotman J; Sebban C; Caballero D; Greil R; van Eygen K; Cohen AM; Gonzalez H; Bouabdallah R; Oberic L; Corront B; Choufi B; Lopez-Guillermo A; Catalano J; Van Hoof A; Briere J; Cabeçadas J; Salles G; Gaulard P; Bosly A; Coiffier B
    J Clin Oncol; 2017 Aug; 35(22):2473-2481. PubMed ID: 28426350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.
    Vitolo U; Chiappella A; Franceschetti S; Carella AM; Baldi I; Inghirami G; Spina M; Pavone V; Ladetto M; Liberati AM; Molinari AL; Zinzani P; Salvi F; Fattori PP; Zaccaria A; Dreyling M; Botto B; Castellino A; Congiu A; Gaudiano M; Zanni M; Ciccone G; Gaidano G; Rossi G;
    Lancet Oncol; 2014 Jun; 15(7):730-7. PubMed ID: 24831981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.
    Nowakowski GS; LaPlant B; Macon WR; Reeder CB; Foran JM; Nelson GD; Thompson CA; Rivera CE; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Ansell SM; Gascoyne RD; Habermann TM; Witzig TE
    J Clin Oncol; 2015 Jan; 33(3):251-7. PubMed ID: 25135992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
    Zinzani PL; Stefoni V; Finolezzi E; Brusamolino E; Cabras MG; Chiappella A; Salvi F; Rossi A; Broccoli A; Martelli M
    Clin Lymphoma Myeloma; 2009 Oct; 9(5):381-5. PubMed ID: 19858058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addictive response of primary cutaneous diffuse large B cell lymphoma leg type to low-dose ibrutinib.
    Pang A; Au-Yeung R; Leung RYY; Kwong YL
    Ann Hematol; 2019 Oct; 98(10):2433-2436. PubMed ID: 31446456
    [No Abstract]   [Full Text] [Related]  

  • 9. Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.
    Fabbri A; Gozzetti A; Rigacci L
    Cancer; 2011 Aug; 117(15):3530; author reply 3531. PubMed ID: 21287541
    [No Abstract]   [Full Text] [Related]  

  • 10. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
    Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
    Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenalidomide Maintenance after R-CHOP Therapy in Diffuse Large B-Cell Lymphoma: Can It Be a Standard of Care.
    Dada R
    Acta Haematol; 2017; 138(4):216-220. PubMed ID: 29212067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment strategy of Hodgkin lymphoma].
    Nagai H
    Rinsho Ketsueki; 2014 Oct; 55(10):1941-51. PubMed ID: 25297759
    [No Abstract]   [Full Text] [Related]  

  • 13. Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone: report of two cases from South America.
    Beltran BE; Castillo JJ; Salas R; Quiñones P; Morales D; Cotrina E; Miranda RN; Sotomayor EM
    Leuk Lymphoma; 2011 Jan; 52(1):153-6. PubMed ID: 21219127
    [No Abstract]   [Full Text] [Related]  

  • 14. Intravascular large B cell lymphoma: widespread but not everywhere.
    Ponzoni M; Ferreri AJ
    Acta Haematol; 2014; 131(1):16-7. PubMed ID: 24021531
    [No Abstract]   [Full Text] [Related]  

  • 15. Rituximab in combination with interferon-alpha in relapsed and refractory diffuse large B-cell non-Hodgkin's lymphoma.
    Bertè R; Vallisa D; Civardi G; Moroni CF; Lazzaro A; Cavanna L
    Acta Haematol; 2001; 106(3):141-2. PubMed ID: 11713384
    [No Abstract]   [Full Text] [Related]  

  • 16. FcγRIIA and FcγRIIIA polymorphisms do not influence survival and response to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy in patients with diffuse large B-cell lymphoma.
    Fabisiewicz A; Paszkiewicz-Kozik E; Osowiecki M; Walewski J; Siedlecki JA
    Leuk Lymphoma; 2011 Aug; 52(8):1604-6. PubMed ID: 21657954
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B).
    Ketterer N; Coiffier B; Thieblemont C; Fermé C; Brière J; Casasnovas O; Bologna S; Christian B; Connerotte T; Récher C; Bordessoule D; Fruchart C; Delarue R; Bonnet C; Morschhauser F; Anglaret B; Soussain C; Fabiani B; Tilly H; Haioun C
    Ann Oncol; 2013 Apr; 24(4):1032-7. PubMed ID: 23235801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab in heavily pretreated cutaneous B-cell lymphoma.
    Zinzani PL; Stefoni V; Alinari L; Vianelli N; Baccarani M
    Leuk Lymphoma; 2003 Sep; 44(9):1637-8. PubMed ID: 14565673
    [No Abstract]   [Full Text] [Related]  

  • 19. Moving beyond rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for diffuse large B-cell lymphoma.
    Roschewski M; Dunleavy K; Wilson WH
    Leuk Lymphoma; 2014 Nov; 55(11):2428-37. PubMed ID: 24438195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab and lenalidomide induced remission in refractory double-hit lymphoma.
    Chan TS; Khong PL; Kwong YL
    Ann Hematol; 2016 Oct; 95(11):1917-8. PubMed ID: 27473194
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.